Literature DB >> 27867982

ASSURE vs. S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics.

Camillo Porta1, Silvia Chiellino2.   

Abstract

Entities:  

Year:  2016        PMID： 27867982      PMCID： PMC5104625          DOI： 10.21037/atm.2016.10.45

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  12 in total

1.  The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters.

Authors:  Brett Delahunt; John C Cheville; Guido Martignoni; Peter A Humphrey; Cristina Magi-Galluzzi; Jesse McKenney; Lars Egevad; Ferran Algaba; Holger Moch; David J Grignon; Rodolfo Montironi; John R Srigley
Journal:  Am J Surg Pathol       Date:  2013-10       Impact factor: 6.394

2.  A postoperative prognostic nomogram for renal cell carcinoma.

Authors:  M W Kattan; V Reuter; R J Motzer; J Katz; P Russo
Journal:  J Urol       Date:  2001-07       Impact factor: 7.450

3.  Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents.

Authors:  Francesco Massari; Emilio Bria; Francesca Maines; Michele Milella; Diana Giannarelli; Francesco Cognetti; Giovanni Pappagallo; Giampaolo Tortora; Camillo Porta
Journal:  Clin Genitourin Cancer       Date:  2013-06-28       Impact factor: 2.872

4.  A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies.

Authors:  Brian Rini; Audrey Goddard; Dejan Knezevic; Tara Maddala; Ming Zhou; Hakan Aydin; Steven Campbell; Paul Elson; Serge Koscielny; Margarita Lopatin; Christer Svedman; Jean-Francois Martini; J Andrew Williams; Virginie Verkarre; Camelia Radulescu; Yann Neuzillet; Isabelle Hemmerlé; Marc Olivier Timsit; Athanasios C Tsiatis; Michael Bonham; Thierry Lebret; Arnaud Mejean; Bernard Escudier
Journal:  Lancet Oncol       Date:  2015-05-12       Impact factor: 41.316

5.  Rapid vascular regrowth in tumors after reversal of VEGF inhibition.

Authors:  Michael R Mancuso; Rachel Davis; Scott M Norberg; Shaun O'Brien; Barbara Sennino; Tsutomu Nakahara; Virginia J Yao; Tetsuichiro Inai; Peter Brooks; Bruce Freimark; David R Shalinsky; Dana D Hu-Lowe; Donald M McDonald
Journal:  J Clin Invest       Date:  2006-10       Impact factor: 14.808

6.  Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.

Authors:  Matteo Santoni; Sebastiano Buti; Alessandro Conti; Camillo Porta; Giuseppe Procopio; Cora N Sternberg; Sergio Bracarda; Umberto Basso; Ugo De Giorgi; Mimma Rizzo; Lisa Derosa; Cinzia Ortega; Francesco Massari; Michele Milella; Melissa Bersanelli; Linda Cerbone; Giovanni Muzzonigro; Luciano Burattini; Rodolfo Montironi; Daniele Santini; Stefano Cascinu
Journal:  Target Oncol       Date:  2015-01-06       Impact factor: 4.493

7.  Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

Authors:  Alain Ravaud; Robert J Motzer; Hardev S Pandha; Daniel J George; Allan J Pantuck; Anup Patel; Yen-Hwa Chang; Bernard Escudier; Frede Donskov; Ahmed Magheli; Giacomo Carteni; Brigitte Laguerre; Piotr Tomczak; Jan Breza; Paola Gerletti; Mariajose Lechuga; Xun Lin; Jean-Francois Martini; Krishnan Ramaswamy; Michelle Casey; Michael Staehler; Jean-Jacques Patard
Journal:  N Engl J Med       Date:  2016-10-09       Impact factor: 91.245

8.  Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.

Authors:  Payal Kapur; Samuel Peña-Llopis; Alana Christie; Leah Zhrebker; Andrea Pavía-Jiménez; W Kimryn Rathmell; Xian-Jin Xie; James Brugarolas
Journal:  Lancet Oncol       Date:  2013-01-16       Impact factor: 41.316

Review 9.  The VHL/HIF axis in clear cell renal carcinoma.

Authors:  Chuan Shen; William G Kaelin
Journal:  Semin Cancer Biol       Date:  2012-06-13       Impact factor: 15.707

10.  Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.

Authors:  Naomi B Haas; Judith Manola; Robert G Uzzo; Keith T Flaherty; Christopher G Wood; Christopher Kane; Michael Jewett; Janice P Dutcher; Michael B Atkins; Michael Pins; George Wilding; David Cella; Lynne Wagner; Surena Matin; Timothy M Kuzel; Wade J Sexton; Yu-Ning Wong; Toni K Choueiri; Roberto Pili; Igor Puzanov; Manish Kohli; Walter Stadler; Michael Carducci; Robert Coomes; Robert S DiPaola
Journal:  Lancet       Date:  2016-03-09       Impact factor: 79.321
View more
  3 in total

Review 1.  Is there a role for adjuvant therapy after surgery in "high risk for recurrence" kidney cancer? An update on current concepts.

Authors:  T Sharma; C Tajzler; A Kapoor
Journal:  Curr Oncol       Date:  2018-10-31       Impact factor: 3.677

Review 2.  Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence.

Authors:  Mimma Rizzo; Camillo Porta
Journal:  Ther Adv Urol       Date:  2017-06-29

3.  Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial.

Authors:  Benjamin T Ristau; Judi Manola; Naomi B Haas; Daniel Y C Heng; Edward M Messing; Christopher G Wood; Christopher J Kane; Robert S DiPaola; Robert G Uzzo
Journal:  J Urol       Date:  2017-07-18       Impact factor: 7.450
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.